Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01660451
Recruitment Status : Active, not recruiting
First Posted : August 8, 2012
Results First Posted : January 8, 2018
Last Update Posted : May 8, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

Tracking Information
First Submitted Date  ICMJE August 6, 2012
First Posted Date  ICMJE August 8, 2012
Results First Submitted Date  ICMJE October 13, 2017
Results First Posted Date  ICMJE January 8, 2018
Last Update Posted Date May 8, 2019
Actual Study Start Date  ICMJE November 19, 2012
Actual Primary Completion Date June 22, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 8, 2017)
  • Objective Response Rate (ORR) Based on Independent Review-Part A [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Objective response rate was defined as the proportion of participants with a best response rating of complete response (CR), unconfirmed complete response (CRu) or partial response (PR), based on the Report of an International Workshop to Standardize Response Criteria for non-Hodgkins Lymphomas, Cheson, 1999, as evaluated by the Independent Response Adjudication Committee (IRAC). For chronic lymphocytic leukemia (CLL) patients Hallek criteria (2008) were used and assessed by investigator.
  • Objective Response Rate (ORR) Based on Independent Review-Part B [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Objective response rate was defined as the proportion of participants with a best response rating of CR or PR, based on the International Working Group Revised response Criteria for Malignant Lymphoma, Cheson 2007.
  • ORR Based on Investigator Assessment-Part A [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Objective response rate was defined as the proportion of participants with a best response rating of CR, CRu or PR, based on the Report of an International Workshop to Standardize Response Criteria for non-Hodgkins Lymphomas, Cheson, 1999. For CLL patients Hallek criteria (2008) were used and assessed by investigator.
  • ORR Based on Investigator Assessment-Part B [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Objective response rate was defined as the proportion of participants with a best response rating of CR or PR, based on the International Working Group Revised response Criteria for Malignant Lymphoma, Cheson 2007.
Original Primary Outcome Measures  ICMJE
 (submitted: August 6, 2012)
Tumor response [ Time Frame: Up to 10 months ]
Objective tumor response (OR) is defined as best response rating of complete response (CR or unconfirmed CR) or partial response (PR) according to the criteria defined in the Report of an International Workshop to Standardize Response Criteria for NHL. In patients with Chronic lymphocytic leukemia (CLL), OR is defined as best response rating of complete response (CR) or partial response (PR) according to the guidelines for the diagnosis and treatment of chronic lymphocytic leukemia of the International Workshop on Chronic Lymphocytic Leukemia.
Change History Complete list of historical versions of study NCT01660451 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 8, 2017)
  • Duration of Response (DOR) Based on Independent Review [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Duration of response (DOR) was defined as the time (in days) from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease [PD], first clinical progression or first adverse event [AE] associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression.
  • DOR Based on Investigator Assessment [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    Duration of response (DOR) was defined as the time (in days) from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease [PD], first clinical progression or first adverse event [AE] associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression.
  • Progression Free Survival (PFS) Based on Independent Review [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
  • PFS Based on Investigator Assessment [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
  • Overall Survival (OS) [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    OS was defined as the time (in days) from the date of first administration of study treatment to death due to any cause.
  • Functional Assessment of Cancer Therapy - Lymphoma Lymphoma Subscale (FACT-Lym LymS) at Week 16 - Part B [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    HRQoL assessment was used to describe development of patients with copanlisib by using FACT-Lym questionnaire assessment tool. It contains 42 items (questions) covering HRQoL, common lymphoma symptoms and treatment side-effects. The FACT - General (FACT-G) questionnaire contains 27 items covering 4 core HRQoL subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 items) (FACT-Lym LymS), addressing issues typically experienced by lymphoma patients. Some of the issues covered include pain, itching, night sweats, trouble sleeping, fatigue and trouble concentrating. FACT-Lym also asks patients about lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. Score range for the FACT-Lym LymS was 0 - 60, higher score represent less symptoms. Here in below table "n" signifies evaluable participants for the respective category.
  • Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Total Score at Week 16 - Part B [ Time Frame: Baseline up to the last patient has completed the 16 weeks of treatment ]
    HRQoL assessment was used to describe development of patients with copanlisib by using FACT-Lym questionnaire assessment tool. It contains 42 items (questions) covering HRQoL, common lymphoma symptoms and treatment side-effects. The FACT - General (FACT-G) questionnaire contains 27 items covering 4 core HRQoL subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 items) (FACT-Lym LymS), addressing issues typically experienced by lymphoma patients. Some of the issues covered include pain, itching, night sweats, trouble sleeping, fatigue and trouble concentrating. FACT-Lym also asks patients about lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. FACT-Lym total score range was 0-168, higher score indicates better HRQoL. Here, in the below table "n" signifies evaluable participants for the respective category.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 6, 2012)
  • Duration of response after 12 months [ Time Frame: After 12 months ]
    Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.
  • Duration of response after 3 years [ Time Frame: After 3 years ]
    Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.
  • Progression free survival after 12 months [ Time Frame: After 12 months ]
    Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).
  • Progression free survival after 3 years [ Time Frame: After 3 years ]
    Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).
  • Overall survival after 12 months [ Time Frame: After 12 months ]
    Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.
  • Overall survival after 3 years [ Time Frame: After 3 years ]
    Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.
  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Up to 4 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Official Title  ICMJE Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Brief Summary

The objective of the study (part A) is to evaluate the efficacy and safety of BAY80-6946 in patients with indolent or aggressive Non-Hodgkin's Lymphoma, who have progressed after standard therapy. 30 patients will be enrolled to both indolent and aggressive disease group. The objective of the study part B (CHRONOS-1) is to evaluate the efficacy and safety of BAY80-6946 in patients with relapsed/refractory follicular lymphoma. 120 patients will be enrolled in the part B of the study. Further objectives are to evaluate the pharmacokinetics and biomarkers. Quality of life will be a further objective of part B of the study.

In a cohort of 20 patients (enrolled both in part A and B) an ECG substudy will be performed to assess the potential for cardiac toxicity and QT/QTc interval prolongation of BAY80-6946.

After an up to 28-day screening period, eligible patients will start treatment with BAY80-6946 at a dose of 0.8 mg/kg (Part A) and at a dose of 60 mg (Part B).

Treatment will be continued until disease has progressed or until another criterion is met for withdrawal from study. An end-of-treatment visit will be performed within 7 days after discontinuation of study treatment. Thirty to 35 days after last study drug administration, a safety followup visit will be performed for the collection of adverse events (AEs) and concomitant medication data. Patients will be contacted quarterly to determine overall survival status up to 4 years after last patient first treatment. Patients who discontinue study drug for reasons other than disease progression will enter the Active Assessment Follow-up period. Once the study is analyzed for survival at 4 years after last patient started study treatment, any patient still on treatment may continue to be treated and followed under a separate provision to be determined (e.g. roll-over-study). The end of study notification to Health Authorities will be based on the completion of the collection of survival data.

The efficacy is measured by the decrease in tumor size. Tumor assessments will be done at Screening, every 8 weeks during Year 1, every 12 weeks during Year 2, and every 6 months during Year 3. Blood samples will be collected for pharmacokinetic analysis. Archival tumor tissue and blood samples will be collected for biomarker analysis (mandatory) and for central pathology review (part B), fresh biopsy tissue will also be collected if available.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphoma, Non-Hodgkin
Intervention  ICMJE Drug: Copanlisib (Aliqopa, BAY80-6946)

BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).

Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.

Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.

Study Arms  ICMJE
  • Experimental: Copanlisib (indolent NHL)
    Part A: Participants in this arm will be patients with indolent NHL.
    Intervention: Drug: Copanlisib (Aliqopa, BAY80-6946)
  • Experimental: Copanlisib (aggressive NHL)
    Part A: Participants in this arm will be patients with aggressive NHL.
    Intervention: Drug: Copanlisib (Aliqopa, BAY80-6946)
  • Experimental: Copanlisib (indolent B-cell NHL)
    Part B: Participants in this arm will be patients with indolent B-cell NHL.
    Intervention: Drug: Copanlisib (Aliqopa, BAY80-6946)
Publications * Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: August 30, 2016)
227
Original Estimated Enrollment  ICMJE
 (submitted: August 6, 2012)
60
Estimated Study Completion Date  ICMJE March 8, 2020
Actual Primary Completion Date June 22, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Indolent NHL:

    • Histologically confirmed diagnosis of follicular lymphoma (FL) grades 1, 2 or 3a, marginal zone lymphoma (including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue [MALT] lymphoma), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, chronic lymphocytic leukemia (CLL).
    • Relapsed after ≥ 2 prior chemotherapy- or immunotherapy-based regimens for indolent NHL, or refractory to 2 prior chemotherapy and/ or immunotherapy-based regimens.
  • Aggressive NHL:

    • Histologically confirmed diagnosis of grade 3b follicular lymphoma (FL), transformed indolent lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), peripheral T-cell lymphoma unspecified, or anaplastic large cell lymphoma primary systemic type, or angioimmunoblastic T cell lymphoma.
    • Relapsed after ≥ 2 prior chemotherapy regimens, including the following: First-line treatment with standard anthracycline-containing regimen (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone or equivalent). At least 1 additional combination chemotherapy regimen. Patients relapsed after or refractory to first prior chemotherapy- and/or immunotherapy-based regimen for aggressive NHL and not eligible for high-dose regimen followed by transplant. High-dose chemotherapy, or chemoradiotherapy with autologous stem cell transplantation is considered 1 regimen. Patients with CD20 expressing neoplastic cells must have received prior rituximab, if available.
    • Patients with transformed indolent lymphoma must have received at least 2 prior chemotherapy- and/or immunotherapy-based regimens
    • Consent to provide fresh tumor tissue during screening
  • Indolent B-cell NHL lymphoma (study part B):

    • Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:

      • Follicular lymphoma (FL) grade 1-2-3a
      • Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entry
      • Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
      • Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)
    • Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have received Rituximab and alkylating agents.
  • For all patients:

    • Male or female patients > 18 years of age
    • ECOG performance status ≤ 2 (ECOG: Eastern Cooperative Oncology Group)
    • Life expectancy of at least 3 months
    • Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment
    • Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) for the Institution
    • Availability of archival tumor tissue

Exclusion Criteria:

  • Uncontrolled hypertension (blood pressure ≥ 150/90 mmHg despite optimal medical management)
  • Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events).
  • History or concurrent condition of interstitial lung disease
  • Unresolved toxicity higher than CTCAE grade 1 (NCI-CTC version 4.0) attributed to any prior therapy/procedure excluding alopecia. (NCI: National Cancer Institute)
  • Prior treatment with PI3K inhibitors
  • Systemic corticosteroid therapy (ongoing)
  • Hepatitis B or C. All subjects must be screened for hepatitis B and C up to 28 days prior to study drug start using the hepatitis virus panel laboratorial routine. Subjects positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA; subjects positive for HCV IgG will be eligible if they are negative for HCV RNA.
  • For Part B:

    • Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease and chronic lymphocytic leukemia (CLL)
    • History or concurrent condition of interstitial lung disease or severely impaired pulmonary function
  • Excluded medical conditions:

    • Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within 5 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
    • Hepatitis B or C. All subjects must be screened for hepatitis B and C up to 28 days prior to study drug start using the hepatitis virus panel laboratorial routine. Subjects positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA; subjects positive for HCV IgG will be eligible if they are negative for HCV-RNA.
    • Type I or II diabetes mellitus with HbA1c > 8.5% or fasting plasma glucose > 160 mg/dL at screening.
    • Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within 5 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Bulgaria,   Canada,   Finland,   France,   Germany,   Greece,   Hong Kong,   Hungary,   Ireland,   Israel,   Italy,   Korea, Republic of,   New Zealand,   Poland,   Portugal,   Russian Federation,   Singapore,   Spain,   Sweden,   Turkey,   United Kingdom,   United States
Removed Location Countries Chile,   China,   Colombia,   Denmark,   Japan,   Luxembourg,   Mexico,   Peru
 
Administrative Information
NCT Number  ICMJE NCT01660451
Other Study ID Numbers  ICMJE 16349
2012-002602-52 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Bayer
Study Sponsor  ICMJE Bayer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Bayer Study Director Bayer
PRS Account Bayer
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP